ERBB3 and ovarian cancer: In a mouse model of human ovarian cancer, depletion of ErbB3 by RNAi reduced tumour growth and prolonged mouse survival, while treatment with a monoclonal anti-ErbB3 antibody (MM-121, Merrimack Pharmaceuticals, Cambridge, MA, USA) also resulted in inhibition of tumour progression (Sheng et al, 2010).